cp wire

CP Wire Articles

5AM Venture Management, LLC (5AM) of San Francisco, CA and Boston, MA announced on 2/13/19 the closing of two new venture capital funds, totaling $497 million in committed capital. The capital was... read more

Thu, 02/14/19 - 09:53 am
admin

Cirius Therapeutics has updated it filing for a planned $86 million IPO. The date of the IPO still hasn't been set.

Cirius' lead candidate, MSDC-0602K, is a once daily, oral treatment for... read more

Thu, 02/14/19 - 09:38 am
admin

Ascletis Pharma Inc. (Ascletis, 1672.HK) and 3-V Biosciences, Inc. (3-V Biosciences) jointly announced on 2/13/19 that Ascletis, through its subsidiary, and 3-V Biosciences have entered into an... read more

Wed, 02/13/19 - 05:02 pm
admin

Beginning on March 1, China will reduce the VAT on a group of 21 rare disease drugs from 16% to 3%. The government's announcement did not specify which drugs would be in the group. The move may... read more

Wed, 02/13/19 - 09:38 am
admin

Yuhan Corporation (000100.KS; Yuhan) and Sorrento Therapeutics (Nasdaq: SRNE) announced on 2/12/19 that ImmuneOncia, a joint venture formed in September 2016, has completed a private equity... read more

Tue, 02/12/19 - 09:55 am
admin

Xeris Pharmaceuticals announced on 2/11/19 that it filed a registration statement with the Securities and Exchange Commission (the “SEC”) relating to a proposed public offering of 5,000,000 shares... read more

Tue, 02/12/19 - 09:41 am
admin

Seattle Genetics (Nasdaq:SGEN) announced on 2/11/19 that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the marketing... read more

Mon, 02/11/19 - 10:11 am
admin

Shockwave Medical filed for its IPO on 2/8/19. While the filing did not list the number of shares to be offered or the expected offering price, the offering will bring in an expected maximum of $... read more

Mon, 02/11/19 - 09:53 am
admin

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced on 2/8/19 that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation... read more

Fri, 02/8/19 - 09:37 am
admin

HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, launched today with $60.75M in Series A funding led by ARCH Venture Partners.... read more

Thu, 02/7/19 - 09:53 am
admin

Vaxart has filed for an upcoming stock offering with the number of shares yet to be announced. Vaxart is developing oral vaccines based on it proprietary oral recombinant vaccine technology. The... read more

Thu, 02/7/19 - 09:37 am
admin

Sunstone Life Science Ventures today announced the first closing of its Sunstone Life Science Ventures Fund IV ("Sunstone LSV IV") at $91 million. The investment strategy of the new fund is a... read more

Wed, 02/6/19 - 12:07 pm
admin

Indivior PLC (LON: INDV) (“Indivior” or the “Company”) announced on 2/2/19 that it has entered into a definitive agreement to divest its rights related to the Sai Bo Song (buprenorphine, naloxone... read more

Wed, 02/6/19 - 09:30 am
admin

Harpoon Therapeutics announced that it will raise up to $93 million in its IPO. The company is offering 5,400,000 shares and is granting underwriters the option to purchase up to an additional 810... read more

Mon, 02/4/19 - 09:16 pm
admin

Avedro, Inc. (“Avedro”), a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or... read more

Mon, 02/4/19 - 10:14 am
admin

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company developing the next generation of novel T cell receptor therapies for patients suffering from cancer, today announced that it has... read more

Sat, 02/2/19 - 03:05 pm
admin

Eli Lilly and Company (NYSE: LLY) (“Lilly”) and Loxo Oncology, Inc. (NASDAQ: LOXO) (“Loxo Oncology”) announcedon 2/1/19 the expiration of the waiting period under the Hart-Scott-Rodino Antitrust... read more

Fri, 02/1/19 - 09:43 am
admin

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced on 1/31/19 that in its lawsuit against Janssen Biotech and Genmab A/S, the parties have settled the... read more

Fri, 02/1/19 - 09:25 am
admin

Pages



current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.